131 related articles for article (PubMed ID: 12721758)
1. The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice.
Abou El Hassan MA; Kedde MA; Zwiers UT; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Apr; 51(4):306-10. PubMed ID: 12721758
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice.
Abou El Hassan MA; Kedde MA; Zwiers UT; Tourn E; Haenen GR; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Nov; 52(5):371-6. PubMed ID: 12898182
[TBL] [Abstract][Full Text] [Related]
3. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
4. The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.
Abou El Hassan MA; Heijn M; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
Cancer Gene Ther; 2003 Apr; 10(4):270-7. PubMed ID: 12679799
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.
Bruynzeel AM; Vormer-Bonne S; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2007 Sep; 60(4):509-14. PubMed ID: 17177067
[TBL] [Abstract][Full Text] [Related]
6. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
7. 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week.
van Acker FA; van Acker SA; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
Clin Cancer Res; 2000 Apr; 6(4):1337-41. PubMed ID: 10778960
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of monohydroxyethylrutoside in healthy volunteers.
Willems AM; Bruynzeel AM; Kedde MA; van Groeningen CJ; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 May; 57(5):678-84. PubMed ID: 16136309
[TBL] [Abstract][Full Text] [Related]
9. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
van Acker FA; Boven E; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
Clin Cancer Res; 2001 May; 7(5):1378-84. PubMed ID: 11350909
[TBL] [Abstract][Full Text] [Related]
10. Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
Jacobs H; Peters R; den Hartog GJ; van der Vijgh WJ; Bast A; Haenen GR
Drug Metab Dispos; 2011 May; 39(5):750-6. PubMed ID: 21266594
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
12. A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.
Abou-El-Hassan MA; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
Br J Cancer; 2003 Dec; 89(11):2140-6. PubMed ID: 14647150
[TBL] [Abstract][Full Text] [Related]
13. Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.
van Acker SA; Kramer K; Grimbergen JA; van den Berg DJ; van der Vijgh WJ; Bast A
Br J Pharmacol; 1995 Aug; 115(7):1260-4. PubMed ID: 7582554
[TBL] [Abstract][Full Text] [Related]
14. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM
Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278
[TBL] [Abstract][Full Text] [Related]
15. Sustained protective effects of 7-monohydroxyethylrutoside in an in vivo model of cardiac ischemia-reperfusion.
De Celle T; Heeringa P; Strzelecka AE; Bast A; Smits JF; Janssen BJ
Eur J Pharmacol; 2004 Jun; 494(2-3):205-12. PubMed ID: 15212976
[TBL] [Abstract][Full Text] [Related]
16. Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
Bast A; Kaiserová H; den Hartog GJ; Haenen GR; van der Vijgh WJ
Cell Biol Toxicol; 2007 Jan; 23(1):39-47. PubMed ID: 17063376
[TBL] [Abstract][Full Text] [Related]
17. The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro.
Abou El Hassan MA; Verheul HM; Jorna AS; Schalkwijk C; van Bezu J; van der Vijgh WJ; Bast A
Br J Cancer; 2003 Jul; 89(2):357-62. PubMed ID: 12865930
[TBL] [Abstract][Full Text] [Related]
18. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
van Asperen J; van Tellingen O; Tijssen F; Schinkel AH; Beijnen JH
Br J Cancer; 1999 Jan; 79(1):108-13. PubMed ID: 10408701
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.
van Acker SA; Voest EE; Beems DB; Madhuizen HT; de Jong J; Bast A; van der Vijgh WJ
Cancer Res; 1993 Oct; 53(19):4603-7. PubMed ID: 8402634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
